[유상증자 모니터] 이뮨온시아, 818억 수혈…자금 계획 조정 불가피한 까닭

Immunonsia successfully attracted oversubscribed interest for its capital increase, avoiding the burden of public offering to retail investors. However, a 32% shortfall in total fundraising (down to 818 billion won) due to lower-than-planned issuance price creates uncertainty about the company's ability to execute its IMC-001 commercialization roadmap and meet its 2031 launch target without additional funding.